When do you really start losing weight on Wegovy — and what shapes the timeline?

The first weeks: why the scales move slowly at first

The question most people are really asking is whether the slow start means the medicine is not working. It almost always does. Wegovy's titration schedule exists for a reason: the body needs time to adjust to semaglutide, and starting at a low dose reduces the nausea and digestive discomfort that can otherwise make treatment hard to sustain. At 0.25mg the appetite effect is gentle. That changes.

Appetite suppression becomes noticeably stronger at 1.0mg and again at 1.7mg. For many people the shift at 1.7mg is the first point at which eating significantly less feels effortless rather than effortful. This typically falls around weeks eight to sixteen, depending on how each dose step goes. Some people tolerate titration quickly; others need an extra month at a given level. Both are normal, and the prescriber decides the pace.

For practical self-monitoring, weighing yourself at the same time each morning (before eating or drinking) gives you a consistent baseline. Day-to-day fluctuations of one to two kilograms reflect fluid shifts, not fat, so a weekly average is more informative than yesterday's single number. That one small habit, taking less than a minute, stops many people losing confidence during a plateau that isn't really a plateau.

The full Wegovy overview covers what the dose steps look like and how the titration schedule is structured.

Months three to twelve: when most of the loss happens

Once someone is established on the 2.4mg maintenance dose, appetite suppression is at its most sustained. Food simply becomes less compelling. Portions reduce without a feeling of deprivation, and many people find they stop thinking about food between meals in a way they hadn't experienced before. This is the mechanism at work: semaglutide acts on GLP-1 receptors involved in appetite signalling and slows gastric emptying, meaning meals satisfy for longer.

The STEP 1 trial, published in the New England Journal of Medicine, followed nearly 2,000 adults with obesity or overweight and a weight-related condition over 68 weeks. Average weight reduction at 2.4mg semaglutide reached around 15%. That figure conceals a wide range: some participants lost considerably more, others less. The trajectory for most followed a pattern of faster loss in the middle months, levelling off as the body found a new equilibrium.

This is also the phase where the distinction between Wegovy starting to work and Wegovy producing visible results becomes clearest, biochemically, it is working from the first injection; the scale just takes time to catch up.

What slows progress, and what the research says about it

Several factors influence how quickly weight falls. Protein intake matters: the appetite reduction from semaglutide can cause people to under-eat overall, and without sufficient protein, some of the weight lost comes from muscle rather than fat. A reduced-calorie diet focused on protein and fibre alongside the medicine is consistently recommended, the NHS's weight-management guidance and the SmPC both frame lifestyle changes as part of the treatment, not optional extras.

Sleep, stress and activity all play a role too. None of this is unique to Wegovy; it applies to any structured weight-loss approach. What the medicine adds is a sustained reduction in appetite that makes those habits easier to maintain. People who have struggled with caloric restriction for years often describe the experience of Wegovy as the first time the effort felt proportionate to the result.

If fewer than 5% of starting weight has been lost after six months at the maintenance dose, NICE guidance suggests that continuing should be reviewed, which is why ongoing clinical oversight matters throughout, not just at the start. Our clinical team reviews every repeat order, not just the first one. Information on weight-loss treatment options more broadly, including how Wegovy sits alongside other approaches, is available on our treatment overview.

Wegovy 7.2mg and what the higher dose changes

In January 2026 the MHRA approved a higher 7.2mg maintenance dose of semaglutide for adults with obesity. A dedicated single-dose 7.2mg pen followed in April 2026. Trial data associated with this dose reported average weight loss of around 20.7% over 72 weeks, narrowing the gap with tirzepatide results considerably. Whether someone is a candidate for the higher dose depends on how they have responded to 2.4mg and their clinical picture; it is not automatically the next step for everyone.

The broader semaglutide timeline (which covers Wegovy and puts the dose changes into context) may also be useful if you are wondering whether switching doses would change your trajectory. If you are new to the medicine, our guides on when you should start losing weight on Wegovy, when weight loss on Wegovy typically begins, and when people generally start to lose weight on Wegovy walk through the timeline in more detail. The MHRA's announcement of the 7.2mg pen approval sets out the licensed indication clearly. Specific dose availability is always confirmed at your clinical review, not assumed.

If you are thinking about starting Wegovy and want a same-day clinical assessment from a GPhC-registered prescriber, you can speak to our prescribers through a free consultation.